Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

CSF Monoamine Metabolite Levels in Alzheimer's and Parkinson's Disease

CSF Monoamine Metabolite Levels in Alzheimer's and Parkinson's Disease Abstract • Levels of the monoamine metabolites homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA), and 3-methoxy 4-hydroxyphenylglycol (MHPG) were measured in lumbar CSF from 32 patients with a clinical diagnosis of Alzheimer's disease (AD) and from 21 patients with Parkinson's disease (PD). The baseline CSF metabolite values did not differ significantly between the two groups of patients, although HVA levels were lowest in patients with PD and in the more severely demented patients with AD. Levels of all three metabolites increased significantly in both patient groups during probenecid administration, but HVA levels were significantly higher in patients with AD than in patients with PD. Within the AD group, those with the most severe dementia had the greatest rise in MHPG levels. Alterations in monoamine metabolite levels in the CSF detected during probenecid administration aid in the differential diagnosis of neurodegenerative diseases such as AD. References 1. Ball MJ: Neuronal loss, neurofibrillary tangles and granulovacuolar degeneration in the hippocampus with aging and dementia: A quantitative study . Acta Neuropathol 1977;37:111-118.Crossref 2. Brun A, Englund E: Regional pattern of degeneration in Alzheimer's disease: Neuronal loss and histopathological grading . Histopathology 1981;5:549-564.Crossref 3. Terry RD: Aging, senile dementia, and Alzheimer's disease . Aging 1976;7:11-14. 4. Davies P, Maloney AJF: Selective loss of central cholinergic neurons in Alzheimer's disease . Lancet 1976;2:1403.Crossref 5. Bowen DM, Smith CB, White P, et al: Neurotransmitter-related enzymes and indices of hypozia in senile dementia and other abiotrophies . Brain 1976;99:459-496.Crossref 6. Perry EK, Gibson PH, Blessed G, et al: Neurotransmitter enzyme abnormalities in senile dementia . J Neurol Sci 1977;34:247-265.Crossref 7. Davies P, Katzman R, Terry RD: Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer's disease and Alzheimer senile dementia . Nature 1980;288:279-280.Crossref 8. Adolfsson R, Gottfries CG, Roos BE, et al: Changes in the brain catecholamines in patients with dementia of Alzheimer type . Br J Psychiatry 1979;135:216-223.Crossref 9. Carlsson A, Adolfsson R, Aquilonius S-M, et al: Biogenic amines in human brain in normal aging, senile dementia, and chronic alcoholism , in Goldstein M, et al (eds): Ergot Compounds and Brain Function: Neuroendocrine and Neuropsychiatric Aspects . New York, Raven Press, 1980, pp 295-304. 10. Gottfries CG, Gottfries I, Roos BE: The investigation of homovanillic acid in the human brain and its correlation to senile dementia . Br J Psychiatry 1969;115:563-574.Crossref 11. Cross AJ, Crow TJ, Johnson JA, et al: Monoamine metabolism in senile dementia of Alzheimer type . J Neurol Sci 1983;60:383-392.Crossref 12. Davies P, Katz DA, Crystal HA: Choline acetyltransferase, somatostatin, and substance P in selected cases of Alzheimer's disease , in Corkin S, Davis K, Growdon JH, et al (eds): Alzheimer's Disease: A Report of Progress in Research . New York, Raven Press, 1982, pp 9-14. 13. Hoehn MM, Yahr MD: Parkinsonism: Onset, progression and mortality . Neurology 1967;17:427-442.Crossref 14. Growdon JH, Logue M: Choline, HVA, and 5-HIAA levels in cerebrospinal fluid of patients with Alzheimer's disease , in Corkin S, Davis K, Growdon JH, et al (eds): Alzheimer's Disease: A Report of Progress in Research . New York, Raven Press, 1982, pp 35-43. 15. Hefti F: A simple, sensitive method for measuring 3,4-dihydroxy-phenylacetic acid and homovanillic acid and rat brain tissue using high performance liquid chromatography with electrochemical detection . Life Sci 1979;25:775-782.Crossref 16. Hekman P, Porskamp PATW, Ketelaars HCJ, et al: Rapid high performance liquid chromatographic methods for the determination of probenecid in biological fluids . J Chromatogr 1980;182:252-256.Crossref 17. Moir ATB, Ashcroft GW, Crowford TBB, et al: Cerebral metabolites in cerebrospinal fluid as a biochemical approach to the brain . Brain 1970; 93:357-368.Crossref 18. Garelis E, Young SN, Lal S, et al: Monoamine metabolites in lumbar CSF: The question of their origin in relation to clinical studies . Brain Res 1974;79:1-8.Crossref 19. Bernheimer H, Birkmayer W, Horynkie-wicz W, et al: Brain dopamine and the syndromes of Parkinson and Huntington . J Neurol Sci 1973; 20:415-455.Crossref 20. Olsson R, Roos BE: Concentrations of 5hydroxyindoleacetic acid and homovanillic acid in the cerebrospinal fluid after treatment with probenecid in patients with Parkinson's disease . Nature 1968;219:502-503.Crossref 21. Davidson DLW, Yates CM, Mawdsley C, et al: CSF studies on the relationship between dopamine and 5-hydroxytryptamine in parkinsonism and other movement disorders . J Neurol Neurosurg Psychiatry 1977;40:1136-1141.Crossref 22. Rossor NM: Parkinson's disease and Alzheimer's disease as disorders of the isodendritic core . Br Med J 1981;283:1587-1590.Crossref 23. Whitehouse PJ, Price DL, Struble RG, et al: Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain . Ann Neurol 1981;10:279-285.Crossref 24. Candy JM, Perry RH, Perry EK, et al: Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases . J Neurol Sci 1983;54:277-289.Crossref 25. Scatton B, Rouquier L, Javor-Agid Y: Dopamine deficiency in the cerebral cortex in Parkinson disease . Neurology 1982;32:1039-1040.Crossref 26. Gottfries CG, Roos BE: Acid monoamine metabolites in cerebrospinal fluid from patients with presenile dementia (Alzheimer's disease) . Acta Psychiatr Scand 1973;49:257-263.Crossref 27. Gottfries CG, Gottfries I, Roos BE: Homovanillic acid and 5-hydroxy-indoleacetic acid in the cerebrospinal fluid of patients with senile dementia, presenile dementia and parkinsonism . J Neurochem 1969;16:1341-1345.Crossref 28. Soininen H, MacDonald E, Rekonen M, et al: Homovanillic acid and 5-hydroxyindoleacetic acid levels in cerebrospinal fluid of patients with senile dementia of Alzheimer type . Acta Neurol Scand 1981;64:101-107.Crossref 29. Korf J, Van Praag HM, Sebens JB: Effect of intravenously administered probenecid in humans on the levels of 5-hydroxyindoleacetic acid, homovanillic acid and 3-methoxy-4hydroxyphenylglycol in cerebrospinal fluid . Biochem Pharmacol 1971;20:659-668.Crossref 30. Ebert MH, Kartzinel R, Crowdry RW, et al: Cerebrospinal fluid amine metabolites and the probenecid test , in Wood JH (ed): Neurobiology of Cerebrospinal Fluid . New York, Plenum Press, 1980, pp 97-112. 31. Wolfson LI, Escriva A: Clearance of 3methoxy-4-hydroxyphenylglycol from the cerebrospinal fluid . Neurology 1976;26:781-784.Crossref 32. Gordon EK, Oliver J, Goodwin FK, et al: Effect of probenecid on free 3-methoxy-4hydroxyphenylethylene glycol (MHPG) and its sulphate in human cerebrospinal fluid . Neuropharmacology 1973;12:391-396.Crossref 33. Karoum F, van Kammen DP, Bunney W, et al: The effects of probenecid on the free and conj ugated 3-methoxy-4-hydroxyphenylglycol (MHPG) in lumbar cerebrospinal fluid . Psychopharmacol Communications 1976;2:141-148. 34. Mann DMA, Lincoln J, Yates PO, et al: Changes in monoamine containing neurones of the human CNS in senile dementia . Br J Psychiatry 1980;136:533-541.Crossref 35. Tomlinson BE, Irving D, Blessed G: Cell loss in the locus coeruleus in senile dementia of Alzheimer type . J Neurol Sci 1981;49:419-428.Crossref 36. Bondareff W, Mountjoy LQ, Roth M: Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia . Neurology 1982;32:164-168.Crossref 37. Davis KL, Hsieh JYK, Levy MI, et al: Cerebrospinal fluid acetylcholine, choline, and senile dementia of the Alzheimer's type . Psychopharmacol Bull 1982;18:193-195. 38. Soininen H, Halonen T, Riekkinen PJ: Acetylcholinesterase activities in cerebrospinal fluid of patients with senile dementia of Alzheimer type . Acta Neurol Scand 1981;64:217-224.Crossref 39. Bareggi SR, Franceschi M, Bonini L, et al: Decreased CSF concentrations of homovanillic acid and γ-aminobutyric acid in Alzheimer's disease . Arch Neurol 1982;39:709-712.Crossref 40. Foster NL, Hare TA, Chase TN: Spinal fluid GABA in Alzheimer's disease . Neurology 1982;33( (suppl 2) ):68. 41. Wood PL, Etienne P, Lal S, et al: Reduced lumbar CSF somatostatin levels in Alzheimer's disease . Life Sci 1982;31:2073-2079.Crossref 42. Beal MF, Growdon JH, Mazurek MF: CSF somatostatin in dementia . Neurology 1984; 34( (suppl 1) ):120.Crossref 43. Kaiya H, Tanaka T, Takeucji K, et al: Decreased level of beta-endorphin-like immunoreactivity in cerebrospinal fluid of patients with senile dementia of Alzheimer type . Life Sci 1983; 33:1039-1043.Crossref 44. Mazurek MF, Growdon JH, Beal MF: CSF vasopressin levels reduced in Alzheimer's disease . Neurology 1984;34( (suppl 1) ):280. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Neurology American Medical Association

CSF Monoamine Metabolite Levels in Alzheimer's and Parkinson's Disease

Loading next page...
 
/lp/american-medical-association/csf-monoamine-metabolite-levels-in-alzheimer-s-and-parkinson-s-disease-KV36yMDYx5
Publisher
American Medical Association
Copyright
Copyright © 1985 American Medical Association. All Rights Reserved.
ISSN
0003-9942
eISSN
1538-3687
DOI
10.1001/archneur.1985.04060050091016
Publisher site
See Article on Publisher Site

Abstract

Abstract • Levels of the monoamine metabolites homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA), and 3-methoxy 4-hydroxyphenylglycol (MHPG) were measured in lumbar CSF from 32 patients with a clinical diagnosis of Alzheimer's disease (AD) and from 21 patients with Parkinson's disease (PD). The baseline CSF metabolite values did not differ significantly between the two groups of patients, although HVA levels were lowest in patients with PD and in the more severely demented patients with AD. Levels of all three metabolites increased significantly in both patient groups during probenecid administration, but HVA levels were significantly higher in patients with AD than in patients with PD. Within the AD group, those with the most severe dementia had the greatest rise in MHPG levels. Alterations in monoamine metabolite levels in the CSF detected during probenecid administration aid in the differential diagnosis of neurodegenerative diseases such as AD. References 1. Ball MJ: Neuronal loss, neurofibrillary tangles and granulovacuolar degeneration in the hippocampus with aging and dementia: A quantitative study . Acta Neuropathol 1977;37:111-118.Crossref 2. Brun A, Englund E: Regional pattern of degeneration in Alzheimer's disease: Neuronal loss and histopathological grading . Histopathology 1981;5:549-564.Crossref 3. Terry RD: Aging, senile dementia, and Alzheimer's disease . Aging 1976;7:11-14. 4. Davies P, Maloney AJF: Selective loss of central cholinergic neurons in Alzheimer's disease . Lancet 1976;2:1403.Crossref 5. Bowen DM, Smith CB, White P, et al: Neurotransmitter-related enzymes and indices of hypozia in senile dementia and other abiotrophies . Brain 1976;99:459-496.Crossref 6. Perry EK, Gibson PH, Blessed G, et al: Neurotransmitter enzyme abnormalities in senile dementia . J Neurol Sci 1977;34:247-265.Crossref 7. Davies P, Katzman R, Terry RD: Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer's disease and Alzheimer senile dementia . Nature 1980;288:279-280.Crossref 8. Adolfsson R, Gottfries CG, Roos BE, et al: Changes in the brain catecholamines in patients with dementia of Alzheimer type . Br J Psychiatry 1979;135:216-223.Crossref 9. Carlsson A, Adolfsson R, Aquilonius S-M, et al: Biogenic amines in human brain in normal aging, senile dementia, and chronic alcoholism , in Goldstein M, et al (eds): Ergot Compounds and Brain Function: Neuroendocrine and Neuropsychiatric Aspects . New York, Raven Press, 1980, pp 295-304. 10. Gottfries CG, Gottfries I, Roos BE: The investigation of homovanillic acid in the human brain and its correlation to senile dementia . Br J Psychiatry 1969;115:563-574.Crossref 11. Cross AJ, Crow TJ, Johnson JA, et al: Monoamine metabolism in senile dementia of Alzheimer type . J Neurol Sci 1983;60:383-392.Crossref 12. Davies P, Katz DA, Crystal HA: Choline acetyltransferase, somatostatin, and substance P in selected cases of Alzheimer's disease , in Corkin S, Davis K, Growdon JH, et al (eds): Alzheimer's Disease: A Report of Progress in Research . New York, Raven Press, 1982, pp 9-14. 13. Hoehn MM, Yahr MD: Parkinsonism: Onset, progression and mortality . Neurology 1967;17:427-442.Crossref 14. Growdon JH, Logue M: Choline, HVA, and 5-HIAA levels in cerebrospinal fluid of patients with Alzheimer's disease , in Corkin S, Davis K, Growdon JH, et al (eds): Alzheimer's Disease: A Report of Progress in Research . New York, Raven Press, 1982, pp 35-43. 15. Hefti F: A simple, sensitive method for measuring 3,4-dihydroxy-phenylacetic acid and homovanillic acid and rat brain tissue using high performance liquid chromatography with electrochemical detection . Life Sci 1979;25:775-782.Crossref 16. Hekman P, Porskamp PATW, Ketelaars HCJ, et al: Rapid high performance liquid chromatographic methods for the determination of probenecid in biological fluids . J Chromatogr 1980;182:252-256.Crossref 17. Moir ATB, Ashcroft GW, Crowford TBB, et al: Cerebral metabolites in cerebrospinal fluid as a biochemical approach to the brain . Brain 1970; 93:357-368.Crossref 18. Garelis E, Young SN, Lal S, et al: Monoamine metabolites in lumbar CSF: The question of their origin in relation to clinical studies . Brain Res 1974;79:1-8.Crossref 19. Bernheimer H, Birkmayer W, Horynkie-wicz W, et al: Brain dopamine and the syndromes of Parkinson and Huntington . J Neurol Sci 1973; 20:415-455.Crossref 20. Olsson R, Roos BE: Concentrations of 5hydroxyindoleacetic acid and homovanillic acid in the cerebrospinal fluid after treatment with probenecid in patients with Parkinson's disease . Nature 1968;219:502-503.Crossref 21. Davidson DLW, Yates CM, Mawdsley C, et al: CSF studies on the relationship between dopamine and 5-hydroxytryptamine in parkinsonism and other movement disorders . J Neurol Neurosurg Psychiatry 1977;40:1136-1141.Crossref 22. Rossor NM: Parkinson's disease and Alzheimer's disease as disorders of the isodendritic core . Br Med J 1981;283:1587-1590.Crossref 23. Whitehouse PJ, Price DL, Struble RG, et al: Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain . Ann Neurol 1981;10:279-285.Crossref 24. Candy JM, Perry RH, Perry EK, et al: Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases . J Neurol Sci 1983;54:277-289.Crossref 25. Scatton B, Rouquier L, Javor-Agid Y: Dopamine deficiency in the cerebral cortex in Parkinson disease . Neurology 1982;32:1039-1040.Crossref 26. Gottfries CG, Roos BE: Acid monoamine metabolites in cerebrospinal fluid from patients with presenile dementia (Alzheimer's disease) . Acta Psychiatr Scand 1973;49:257-263.Crossref 27. Gottfries CG, Gottfries I, Roos BE: Homovanillic acid and 5-hydroxy-indoleacetic acid in the cerebrospinal fluid of patients with senile dementia, presenile dementia and parkinsonism . J Neurochem 1969;16:1341-1345.Crossref 28. Soininen H, MacDonald E, Rekonen M, et al: Homovanillic acid and 5-hydroxyindoleacetic acid levels in cerebrospinal fluid of patients with senile dementia of Alzheimer type . Acta Neurol Scand 1981;64:101-107.Crossref 29. Korf J, Van Praag HM, Sebens JB: Effect of intravenously administered probenecid in humans on the levels of 5-hydroxyindoleacetic acid, homovanillic acid and 3-methoxy-4hydroxyphenylglycol in cerebrospinal fluid . Biochem Pharmacol 1971;20:659-668.Crossref 30. Ebert MH, Kartzinel R, Crowdry RW, et al: Cerebrospinal fluid amine metabolites and the probenecid test , in Wood JH (ed): Neurobiology of Cerebrospinal Fluid . New York, Plenum Press, 1980, pp 97-112. 31. Wolfson LI, Escriva A: Clearance of 3methoxy-4-hydroxyphenylglycol from the cerebrospinal fluid . Neurology 1976;26:781-784.Crossref 32. Gordon EK, Oliver J, Goodwin FK, et al: Effect of probenecid on free 3-methoxy-4hydroxyphenylethylene glycol (MHPG) and its sulphate in human cerebrospinal fluid . Neuropharmacology 1973;12:391-396.Crossref 33. Karoum F, van Kammen DP, Bunney W, et al: The effects of probenecid on the free and conj ugated 3-methoxy-4-hydroxyphenylglycol (MHPG) in lumbar cerebrospinal fluid . Psychopharmacol Communications 1976;2:141-148. 34. Mann DMA, Lincoln J, Yates PO, et al: Changes in monoamine containing neurones of the human CNS in senile dementia . Br J Psychiatry 1980;136:533-541.Crossref 35. Tomlinson BE, Irving D, Blessed G: Cell loss in the locus coeruleus in senile dementia of Alzheimer type . J Neurol Sci 1981;49:419-428.Crossref 36. Bondareff W, Mountjoy LQ, Roth M: Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia . Neurology 1982;32:164-168.Crossref 37. Davis KL, Hsieh JYK, Levy MI, et al: Cerebrospinal fluid acetylcholine, choline, and senile dementia of the Alzheimer's type . Psychopharmacol Bull 1982;18:193-195. 38. Soininen H, Halonen T, Riekkinen PJ: Acetylcholinesterase activities in cerebrospinal fluid of patients with senile dementia of Alzheimer type . Acta Neurol Scand 1981;64:217-224.Crossref 39. Bareggi SR, Franceschi M, Bonini L, et al: Decreased CSF concentrations of homovanillic acid and γ-aminobutyric acid in Alzheimer's disease . Arch Neurol 1982;39:709-712.Crossref 40. Foster NL, Hare TA, Chase TN: Spinal fluid GABA in Alzheimer's disease . Neurology 1982;33( (suppl 2) ):68. 41. Wood PL, Etienne P, Lal S, et al: Reduced lumbar CSF somatostatin levels in Alzheimer's disease . Life Sci 1982;31:2073-2079.Crossref 42. Beal MF, Growdon JH, Mazurek MF: CSF somatostatin in dementia . Neurology 1984; 34( (suppl 1) ):120.Crossref 43. Kaiya H, Tanaka T, Takeucji K, et al: Decreased level of beta-endorphin-like immunoreactivity in cerebrospinal fluid of patients with senile dementia of Alzheimer type . Life Sci 1983; 33:1039-1043.Crossref 44. Mazurek MF, Growdon JH, Beal MF: CSF vasopressin levels reduced in Alzheimer's disease . Neurology 1984;34( (suppl 1) ):280.

Journal

Archives of NeurologyAmerican Medical Association

Published: May 1, 1985

References